Compounds for use in the treatment of epilepsy
Inventors
BOILEAU, Céline • CREPEL, Valérie • DEFORGES, Séverine • MASANTE, Julie • MULLE, Christophe • PERET, Angélique • Danos, Olivier • Mercer, Andrew
Assignees
Aix-Marseille Université • Centre National de la Recherche Scientifique • Institut National de la Santé et de la Recherche Médicale • Université de Bordeaux • Regenxbio Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure relates to gene therapy targeting GluK2 subunit that can be used to inhibit epileptiform discharges. Short interfering RNA sequences against the human Grik2 gene sequence are described which are efficient in decreasing the expression of GluK2-containing KARs in neurons engineered to express the equivalent shRNA or miRNA. Using a tissue culture model of TLE, the examples remarkably demonstrate that viral expression of shRNA or miRNA inhibits the frequency of epileptiform discharges. Therefore, RNA therapeutics aimed at decreasing the expression of GluK2-containing KARs in neurons can remarkably prevent spontaneous epileptiform discharges in TLE. In particular, the present disclosure relates to a recombinant antisense oligonucleotide that targets a Grik2 mRNA. The present disclosure also relates to a method for treating epilepsy in a subject in need thereof, wherein the method comprises: administering an effective amount of a vector comprising an oligonucleotide encoding an inhibitory RNA that binds (e.g., hybridizes) specifically to Grik2 mRNA and inhibits expression of Grik2 in the subject.
Core Innovation
The invention provides recombinant antisense oligonucleotides, expression cassettes, and vectors targeting Grik2 mRNA for treating or ameliorating temporal lobe epilepsy. The guide sequence comprises sequence identity to specified reference targets to direct RNA interference. This therapeutic approach reduces neuronal GluK2-containing kainate receptors and associated GluK2 protein levels in affected neural tissues.
The disclosed expression cassettes incorporate stem-loop architectures, neuronal promoters, and viral delivery vectors. In neuronal and hippocampal-slice models of temporal lobe epilepsy, targeted Grik2 knockdown significantly reduces the frequency of epileptiform discharges toward levels observed in GluK2-deficient tissue. These constructs provide targeted molecular intervention for neurological seizure activity.
Claims Coverage
The claims identify one independent claim directed to Grik2-targeting antisense constructs for temporal lobe epilepsy, encompassing one main inventive feature.
Grik2-targeting antisense treatment for temporal lobe epilepsy
The independent claim covers administering to a subject in need thereof a recombinant antisense oligonucleotide comprising a guide sequence targeting Grik2 mRNA with at least 85% sequence identity to specified sequences, or an expression cassette comprising the oligonucleotide, or a vector comprising the expression cassette, with dependent claims further reciting vector types, cassette architectures, promoters, and pharmaceutical compositions.
The claim centers on treating or ameliorating temporal lobe epilepsy using a Grik2-targeting antisense oligonucleotide, an expression cassette, or a vector comprising the cassette.
Stated Advantages
Targeted Grik2 RNA interference via viral shRNA or miRNA expression significantly reduces epileptiform-discharge frequency in neuronal and tissue-culture models of temporal lobe epilepsy, approaching levels observed in GluK2-deficient models.
Documented Applications
Treatment or amelioration of temporal lobe epilepsy in a subject in need thereof using a Grik2-targeting recombinant antisense oligonucleotide, expression cassette, or vector.
Treatment of related epilepsies.
Interested in licensing this patent?